Avicanna Announces Scientific and Medical Affairs Collaboration with Vectura Fertin Pharma
16. Januar 2025 07:30 ET
|
Avicanna Inc.
TORONTO, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on...
Avicanna Completes First Delivery of Proprietary Topical Products to Multinational Pharmaceutical Company
02. Dezember 2024 07:30 ET
|
Avicanna Inc.
TORONTO, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on...
Avicanna Reports Q3 2024
14. November 2024 17:18 ET
|
Avicanna Inc.
9-month revenue of $18.8 million, representing a 75% increase from 2023. Consolidated Gross Margins of 57%, during Q3 2024. TORONTO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or...
Avicanna Announces Closing of Non-Brokered Private Placement
04. November 2024 17:30 ET
|
Avicanna Inc.
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES...
Avicanna Announces Medical Cannabis Real World Evidence Study through MyMedi.ca
23. September 2024 07:25 ET
|
Avicanna Inc.
TORONTO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing,...
Avicanna Announces Repayment of Debentures
30. August 2024 07:30 ET
|
Avicanna Inc.
TORONTO, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on...
Avicanna Announces Closing of Non-Brokered Private Placement
28. August 2024 18:15 ET
|
Avicanna Inc.
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES...
Avicanna Announces United States Patent and Trademark Office Issuance of Patent on Topical Technology
27. August 2024 07:30 ET
|
Avicanna Inc.
USPTO issues Patent No. US 20230025693A1 (“Patent”) that covers Avicanna’s deep penetrating topicalcannabinoid composition and methods for treating musculoskeletal inflammation and pain ...
Avicanna Subsidiary Completes Export of Aureus Branded CBG into Denmark
15. August 2024 07:30 ET
|
Avicanna Inc.
TORONTO, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and...
Avicanna Reports Q2 2024
14. August 2024 17:45 ET
|
Avicanna Inc.
Q2 2024 revenue of $6.1 million an increase of 85% over Q2 2023Completion of two real world evidence trials on Epidermolysis Bullosa and Musculoskeletal Pain TORONTO, Aug. 14, 2024 (GLOBE NEWSWIRE)...